|

TY-9591 Clinical Trials

2 actively recruiting trials

Also known as: TY-9591 Tablets

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • TYK Medicines, Inc2

Indications

  • EGFR Activating Mutation2
  • NSCLC2
  • Lung Cancer2
  • Cancer2
  • Brain Metastases1

Other2 trials

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.